{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:05:18Z","timestamp":1781827518169,"version":"3.54.5"},"reference-count":19,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2013,5,22]],"date-time":"2013-05-22T00:00:00Z","timestamp":1369180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2013,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>The development of herpes zoster is associated with reduced varicella zoster virus (VZV)\u2010specific cell\u2010mediated immune (CMI) reactions. In this study, VZV\u2010specific CMI reactions in 42 anti\u2010VZV\u2010IgG antibody\u2010positive adults infected with HIV\u20101 were evaluated by measuring the IFN\u2010\u03b3 production levels in whole blood in response to stimulation with ultraviolet light\u2010inactivated live attenuated VZV vaccine. The median VZV\u2010specific IFN\u2010\u03b3 production level in all patients was 63\u2009pg\/ml. Antiretroviral therapy (ART)\u2010na\u00efve patients with an AIDS\u2010defining illness (HIV classification category C) had significantly lower IFN\u2010\u03b3 production than ART\u2010na\u00efve patients in categories A and B and patients receiving ART (<jats:italic>P<\/jats:italic>\u2009=\u20090.0194 and <jats:italic>P<\/jats:italic>\u2009=\u20090.0046, respectively). IFN\u2010\u03b3 production increased significantly in patients within 1 month of the onset of recurrent VZV disease and at more than 1 year from onset, compared with patients who had never had recurrent VZV disease (<jats:italic>P<\/jats:italic>\u2009=\u20090.0396 and <jats:italic>P<\/jats:italic>\u2009=\u20090.0484, respectively). In multivariate analyses, category C and history of recurrent VZV disease were significant factors affecting IFN\u2010\u03b3 production. Levels of IFN\u2010\u03b3 were measured before and after ART in seven ART\u2010na\u00efve patients with no history of recurrent VZV disease, and no significant changes were observed. The results indicate that VZV\u2010specific CMI reactions were reduced in patients with an AIDS\u2010defining illness and enhanced in patients with a history of recurrent VZV disease, but not enhanced by ART alone. Vaccination may be necessary to inhibit the development of herpes zoster in patients receiving ART; this IFN\u2010\u03b3 releasing assay is one useful method for evaluating VZV\u2010specific CMI reactions in clinical settings. <jats:bold><jats:italic>J. Med. Virol. 85:1313\u20131320, 2013<\/jats:italic><\/jats:bold>. \u00a9 2013 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jmv.23611","type":"journal-article","created":{"date-parts":[[2013,5,22]],"date-time":"2013-05-22T21:23:21Z","timestamp":1369257801000},"page":"1313-1320","source":"Crossref","is-referenced-by-count":8,"title":["Evaluation of VZV\u2010specific cell\u2010mediated immunity in adults infected with HIV\u20101 by using a simple IFN\u2010\u03b3 release assay"],"prefix":"10.1002","volume":"85","author":[{"given":"Dai","family":"Watanabe","sequence":"first","affiliation":[{"name":"AIDS Medical Center National Hospital Organization Osaka National Hospital Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruhito","family":"Otani","sequence":"additional","affiliation":[{"name":"Department of Public Health Hyogo College of Medicine Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Suzuki","sequence":"additional","affiliation":[{"name":"AIDS Medical Center National Hospital Organization Osaka National Hospital Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Dohi","sequence":"additional","affiliation":[{"name":"AIDS Medical Center National Hospital Organization Osaka National Hospital Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Hirota","sequence":"additional","affiliation":[{"name":"AIDS Medical Center National Hospital Organization Osaka National Hospital Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Yonemoto","sequence":"additional","affiliation":[{"name":"AIDS Medical Center National Hospital Organization Osaka National Hospital Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Koizumi","sequence":"additional","affiliation":[{"name":"AIDS Medical Center National Hospital Organization Osaka National Hospital Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Otera","sequence":"additional","affiliation":[{"name":"AIDS Medical Center National Hospital Organization Osaka National Hospital Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keishiro","family":"Yajima","sequence":"additional","affiliation":[{"name":"AIDS Medical Center National Hospital Organization Osaka National Hospital Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuharu","family":"Nishida","sequence":"additional","affiliation":[{"name":"AIDS Medical Center National Hospital Organization Osaka National Hospital Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Uehira","sequence":"additional","affiliation":[{"name":"AIDS Medical Center National Hospital Organization Osaka National Hospital Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Shima","sequence":"additional","affiliation":[{"name":"Department of Public Health Hyogo College of Medicine Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Shirasaka","sequence":"additional","affiliation":[{"name":"AIDS Medical Center National Hospital Organization Osaka National Hospital Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiomi","family":"Okuno","sequence":"additional","affiliation":[{"name":"Department of Microbiology Hyogo College of Medicine Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,5,22]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000237830.33228.c3"},{"key":"e_1_2_7_3_1","unstructured":"BensonC HuaL AndersenJ JiangJ BozzoloD AnnunziatoP ReadS PollardR RusinD LennoxJ.2012.ZOSTAVAX is generally safe and immunogenic in HIV+ adults virologically suppressed on ART: Results of a phase 2 randomized double\u2010blind placebo\u2010controlled trial. conference on retroviruses and opportunistic infections. Seattle WA."},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318266cd3c"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/166.5.1153"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2010.0340"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01136-11"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(94)31142-0"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000178408.62675.b0"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013441"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00482-10"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1258\/095646205774357271"},{"key":"e_1_2_7_13_1","first-page":"1","article-title":"Guidelines for the prevention and treatment of opportunistic infections among HIV\u2010exposed and HIV\u2010infected children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics","volume":"58","author":"Mofenson LM","year":"2009","journal-title":"MMWR Recomm Rep"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2009.09.010"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2012.01.003"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051016"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1086\/514077"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199604000-00007"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1086\/422011"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.6.4.10654"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjmv.23611","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.23611","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T18:37:19Z","timestamp":1698691039000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.23611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,22]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["10.1002\/jmv.23611"],"URL":"https:\/\/doi.org\/10.1002\/jmv.23611","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,22]]}}}